|
1
|
Zimmet P, Alberti KG, Magliano DJ and
Bennett PH: Diabetes mellitus statistics on prevalence and
mortality: facts and fallacies. Nat Rev Endocrinol 12(10). 616–622.
2016. View Article : Google Scholar
|
|
2
|
Rowley WR, Bezold C, Arikan Y, Byrne E and
Krohe S: Diabetes 2030: Insights from yesterday, today, and future
trends. Popul Health Manag. 20:6–12. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rowley WR and Bezold C: Creating public
awareness: State 2025 diabetes forecasts. Popul Health Manag.
15:194–200. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ahlqvist E, Van Zuydam NR, Groop LC and
McCarthy MI: The genetics of diabetic complications. Nat Rev
Nephrol. 11:277–287. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
American Diabetes Association: Standards
of medical care in diabetes-2014. Diabetes Care 37(Supplement 1).
S14–S80. 2014. View Article : Google Scholar
|
|
6
|
Navarro-González JF, Jarque A, Muros M,
Mora C and García J: Tumor necrosis factor-alpha as a therapeutic
target for diabetic nephropathy. Cytokine Growth Factor Rev.
20:165–173. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lei L, Mao Y, Meng D, Zhang X, Cui L, Huo
Y and Wang Y: Percentage of circulating CD8+ T lymphocytes is
associated with albuminuria in type 2 diabetes mellitus. Exp Clin
Endocrinol Diabetes. 122:27–30. 2014.PubMed/NCBI
|
|
8
|
Fried LF, Emanuele N, Zhang JH, Brophy M,
Conner TA, Duckworth W, Leehey DJ, McCullough PA, O'Connor T,
Palevsky PM, et al: Combined angiotensin inhibition for the
treatment of diabetic nephropathy. N Engl J Med. 369:1892–1903.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nordquist L, Friederich-Persson M,
Fasching A, Liss P, Shoji K, Nangaku M, Hansell P and Palm F:
Activation of hypoxia-inducible factors prevents diabetic
nephropathy. J Am Soc Nephrol. 26:328–338. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tian YM, Guan Y, Li N, Ma HJ, Zhang L,
Wang S and Zhang Y: Chronic intermittent hypobaric hypoxia
ameliorates diabetic nephropathy through enhancing HIF1 signaling
in rats. Diabetes Res Clin Pract. 118:90–97. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hong Q, Li O, Zheng W, Xiao WZ, Zhang L,
Wu D, Cai GY, He JC and Chen XM: LncRNA HOTAIR regulates HIF-1α/AXL
signaling through inhibition of miR-217 in renal cell carcinoma.
Cell Death Dis. 8:e27722017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xiang S, Gu H, Jin L, Thorne RF, Zhang XD
and Wu M: LncRNA IDH1-AS1 links the functions of c-Myc and HIF1α
via IDH1 to regulate the Warburg effect. Proc Natl Acad Sci U S A.
115:E1465–E1474. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin A, Li C, Xing Z, Hu Q, Liang K, Han L,
Wang C, Hawke DH, Wang S, Zhang Y, et al: The LINK-A lncRNA
activates normoxic HIF1α signalling in triple-negative breast
cancer. Nat Cell Biol. 18:213–224. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Mothods. 25:402–408. 2001.
|
|
15
|
Chen S, Dong C, Qian X, Huang S, Feng Y,
Ye X, Miao H, You Q, Lu Y and Ding D: Microarray analysis of long
noncoding RNA expression patterns in diabetic nephropathy. J
Diabetes Complications. 31:569–576. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Long J and Danesh FR: Values and
limitations of targeting lncRNAs in diabetic nephropathy. Diabetes.
67:552–553. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wasung ME, Chawla LS and Madero M:
Biomarkers of renal function, which and when? Clin Chim Acta.
438:350–357. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fufaa GD, Weil EJ, Lemley KV, Knowler WC,
Brosius FC 3rd, Yee B, Mauer M and Nelson RG: Structural predictors
of loss of renal function in American Indians with type 2 diabetes.
Clin J Am Soc Nephrol. 11:254–261. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Maezawa Y, Takemoto M and Yokote K: Cell
biology of diabetic nephropathy: Roles of endothelial cells,
tubulointerstitial cells and podocytes. J Diabetes Investig.
6:3–15. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen J, Chen JK and Harris RC: EGF
receptor deletion in podocytes attenuates diabetic nephropathy. J
Am Soc Nephrol. 26:1115–1125. 2015. View Article : Google Scholar : PubMed/NCBI
|
